anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A method for preparing amorphous itraconazole is provided to prevent solubility reduction and body absorption reduction. CONSTITUTION: A crystallinity of itraconazole is removed by controlling temperature in a range of 165-175 deg.C. A method for preparing a formulation containing itraconazole comprises: a step of preparing amorphous itraconazole and a step of formulation of the amorphous itraconazole. The method also comprises a step of adding 0.01-25%(w/w) of a drying agent. The drying agent includes colloidal silica, hard silicic acid anhydride, heavy silicic acid anhydride, sodium chloride, potassium aluminosilicate, calcium aluminosilicate, or a mixture thereof. The drying agent contains lactose.
PURPOSE:To obtain a fragrant healthy tea, good in taste and expectable pharmacodynamic effects such as sedative or quiet sleep effects by constructing the healthy tea from a granular or a powdery substance prepared by roasting Zizyphi Spinosi Semen which is a dried mature seed of Zizyphus vulgaris Lam. var. spinosus Bunge. CONSTITUTION:This healthy tea is obtained by roasting Zizyphi Spinosi Semen, prepared by drying a mature seed of Zizyphus vulgaris Lam. var. spinosus Bunge and applied as a sedative or a hypnotic agent to insomnia, etc., and then pulverizing or cutting the roasted seed into a granular or a powdery form. The resultant granule or powder can be placed in a teapot or a tea strainer, etc., and hot water is simply poured thereon. Thereby, the granule or powder can readily be drunk as the healthy tea.
PURPOSE:A drug carrier, consisting of a protein, particularly apolipoprotein derived from the living body and a lipid, containing a drug therein, and capable of facilitating the transfer of the drug from blood to the target tissue by intravenous injection. CONSTITUTION:A drug carrier consisting of a protein and a lipid. Apolipoprotein which is a constituent component of lipoprotein in blood derived from humans and animals is used as the protein. Phospholipid, neutral lipid or sterol derived from natural products or a mixture thereof is used as the lipid. The constitution ratio between the protein and the lipid is not critical, but preferably within the usual range of the lipoprotein in blood. The titled carrier is capable of making the drug present in a dispersion state or mixed micelle (complex) state in the carrier, and transferring the drug from blood selectively and rapidly to the tissue. The carrier is obtained by applying physiological properties of the apolipoprotein for utilization as the drug carrier.
von Willebrand disease (VWD) is the most common inherited bleeding disorder. The disorder is characterized by excessive mucocutaneous bleeding. The most common bleeding manifestations of this condition include nosebleeds, bruising, bleeding from minor wounds, menorrhagia or postpartum bleeding in women as well as bleeding after surgery. Other less frequent symptoms include gastrointestinal bleeding, haematomas or haemarthroses. VWD pathophysiology is complex and results from defects in von Willebrand factor (VWF) glycoprotein. Quantitative deficiencies are responsible for type 1 VWD with a partial decrease of VWF and type 3 with the complete absence of VWF. Qualitative abnormalities cause type 2 VWD, being further divided into types 2A, 2B, 2M and 2N. Although common, VWD is at risk of misdiagnosis, overdiagnosis and underdiagnosis owing to several factors, including complex diagnosis, variability of bleeding symptoms, presence of external variables (blood groups and other physiological modifiers such as exercise, thyroid hormones, oestrogens, and ageing), and lack of disease awareness among non-specialist health-care providers. Establishing the correct VWD diagnosis requires an array of specialized phenotypic assays and/or molecular genetic testing of the VWF gene. The management of bleeding includes increasing endogenous VWF levels with desmopressin or infusion of exogenous VWF concentrates (plasma-derived or recombinant). Fibrinolytic inhibitors, topical haemostatic agents and hormonal therapies are used as effective adjunctive measures.
The method involves receiving input data of laboratory tests i.e. blood tests, by making call to a first hardware processor. The input data of laboratory tests are stored in their native formats, and are converted into integrated formats to obtain integrated laboratory test data. The test data with integrated formats are correlated by a health identification code i.e. logical observation identifier name and code, to obtain the correlated data, by utilizing a second hardware processor. The correlated data are recorded in a single document e.g. spreadsheet, by using a third hardware processor. The integrated formats are supported on Java(RTM: programming language) script object notation.
The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
In developed countries, calcific aortic stenosis (CAS) has become the most common acquired valvular disease and cause for valve replacement. The prevalence of the disease increases with age, reaching over 5 % in adults over 75 years of age. The cases of CAS are classified as either of a previously normal (tricuspid) aortic valve (senile, syn. age - related, "sclerotic" type), or based on a congenitally malformed, usually bicuspid aortic valve. This paper is a brief summary of our 5 previous publications from the years 2007 - 2021, devoted to histopathology of CAS, namely to vascularization, inflammatory infiltrate and metaplastic ossification of the valve, and also to topography of these lesions in individual valve cusps. We conclude that calcification of the aortic valve is not a passive degenerative lesion, but an active multifactorial inflammatory process driven by cells native to the aortic valve. Pathogenesis of CAS is similar to that of atherosclerosis.
Depression is a major chronic mental illness worldwide, characterized by anhedonia and pessimism. Exposed to the same stressful stimuli, some people behave normally, while others exhibit negative behaviors and psychology. The exact molecular mechanisms linking stress-induced depressive susceptibility and resilience remain unclear. Connexin 43 (Cx43) forms gap junction channels between the astrocytes, acting as a crucial role in the pathogenesis of depression. Cx43 dysfunction could lead to depressive behaviors, and depression down-regulates the expression of Cx43 in the prefrontal cortex (PFC). Besides, accumulating evidence indicates that inflammation is one of the most common pathological features of the central nervous system dysfunction. However, the roles of Cx43 and peripheral inflammation in stress-susceptible and stress-resilient individuals have rarely been investigated. Thus, animals were classified into the chronic unpredictable stress (CUS)-susceptible group and the CUS-resilient group based on the performance of behavioral tests following the CUS protocol in this study. The protein expression of Cx43 in the PFC, the Cx43 functional changes in the PFC, and the expression levels including interleukin (IL)-1β, tumor necrosis factor-α, IL-6, IL-2, IL-10, and IL-18 in the peripheral serum were detected. Here, we found that stress exposure triggered a significant reduction in Cx43 protein expression in the CUS-susceptible mice but not in the CUS-resilient mice accompanied by various Cx43 phosphorylation expression and the changes of inflammatory signals. Stress resilience is associated with Cx43 in the PFC and fluctuation in inflammatory signaling, showing that therapeutic targeting of these pathways might promote stress resilience.
It is well understood that diabetes mellitus (DM) causes various micro- and macrovascular complications. Among them, coronary heart diseases (CHDs) claim most mortality, and diabetes has been considered as "CHD equivalent". Furthermore, the risk of CHD has been noticed to increase in the pre-diabetic stage, suggesting the development of CHD may start in a rather early stage of the disease. Thus, early detection of CHD in diabetic patients seems to be important. However, currently exam methods for CHD in diabetic patients seemed to have their limitations.

Developed in the 1960s, magnetocardiography (MCG) is designed to detect the weak magnetic field generated by the electrical activity of the heart, and has been used widely in the study of fetal cardiac electrophysiology, arrhythmia and ischemic heart disease. However, the MCG pattern in diabetic patients is not fully understood. The aim of the study is to clarify the correlation among various cardiovascular risk factors and MCG pattern in diabetic patients. And, according to the results of the study, we'll evaluate the potentiality of MCG in early diagnosis of CHD in diabetic patients.
PURPOSE:To provide the titled structure containing lactose monofatty acid ester, having specific orientation to hepatic cells, especially hepatocytes, and useful for medical purpose. CONSTITUTION:A lipid membrane structure (a particle having a membrane structure wherein the polar group of a polar lipid is oriented to the aqueous phase at the interface) taking the form of liposome, water-soluble micelle, micro- emulsion, etc. can be prepared by using a lactose monofatty acid ester (a compound composed of a lactose and a 12-30C acyl group bonded to a hydroxyl group of the glycosyl group of the lactose, and prepared by reacting lactose with an acylation agent). The kind of the lipid membrane structure can be varied by varying the ratio of the lactose monofatty acid ester to the whole lipid component. The molar ratio of the ester to the whole lipid membrane component is preferably >=1/40 to obtain a structure orientable to hepatocyte. The structure can be produced in large amount in high reproducibility.
The primary hypothesis is that the CH505 TF chTrimer vaccine will expand B cell precursor lineages capable of ultimately producing autologous and heterologous Tier 2 broadly neutralizing antibodies (bnAbs). Participants will receive CH505 TF chTrimer plus via two intramuscular injections administered five times throughout the study. Participants will be evaluated for safety and immune responses through blood collection at specified timepoints throughout the study. Each participant will have up to 18 months of scheduled clinic visits and will have a follow-up safety assessment 12 months after their final vaccination. 3M-052-AF (at either a 3 mcg dose or a 5 mcg dose), with or without Alum, via two intramuscular injections administered five times throughout the study. Participants will be evaluated for safety and immune responses through blood collection at specified timepoints throughout the study. Each participant will have up to 18 months of scheduled clinic visits and will have a follow-up safety assessment 12 months after their final vaccination.
Adult Patients with Type 1 Diabetes 

In an open-label, controlled study (Study A), patients with type 1 diabetes (n=546), were randomized to basal-bolus treatment with TOUJEO or LANTUS and treated for 26 weeks. TOUJEO and LANTUS were administered once daily in the morning (time period covering from pre-breakfast until pre-lunch) or in the evening (time period defined as prior to the evening meal until at bedtime). A mealtime insulin analogue was administered before each meal. Mean age was 47 years and mean duration of diabetes was 21 years. Fifty-seven percent were male, 85% were White, 5% Black or African American, and 5% were Hispanic or Latino; 32% of patients had GFR >90 mL/min/1.73 m2. The mean BMI was approximately 27.6 kg/m2. At week 26, treatment with TOUJEO provided a mean reduction in HbA1c that met the prespecified noninferiority margin of 0.4% (Table 4). Patients treated with TOUJEO used 18% more basal insulin than patients treated with LANTUS. There were no clinically important differences in glycemic control when TOUJEO was administered once daily in the morning or in the evening. There were no clinically important differences in body weight between treatment groups.

Pediatric Patients with Type 1 Diabetes

The efficacy of TOUJEO was evaluated in a 26-week, randomized, open-label, multicenter trial (Study B) in 463 pediatric patients with type 1 diabetes mellitus. Patients were randomized to basal-bolus treatment with TOUJEO or LANTUS and treated for 26 weeks. TOUJEO and LANTUS were administered once daily in the morning or in the evening. A mealtime insulin analogue was administered before each meal.

The mean age of the trial population was 13 years; 31% were <12 years of age, 69% were ages ≥12 years of age. The mean duration of diabetes was 6 years. Of the 463 pediatric patients, 51% were male, 92% were White, 3% were Black or African American, and 30% were Hispanic or Latino. The mean baseline BMI percentile was 68.32.

At week 26, the difference in HbA1c reduction from baseline between TOUJEO and LANTUS was 0.02% with a 95% confidence interval (-0.16%; 0.20%) and met the prespecified noninferiority margin (0.3%). The results are presented in Table 5.
Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
We will: 1) compare performance of healthy volunteers and ambulatory adults with traumatic brain injury (TBI) on a range of motor, neurobehavioral and brain imaging outcomes; and 2) evaluate effects of rapid, reciprocal arm and leg exercise with an elliptical trainer on high-level motor coordination and balance, and neurobehavioral and cognitive functioning in persons with TBI. Brain connectivity and changes in connectivity in response to intervention will be quantified. We hypothesize even highly functional adults with TBI will have poorer scores on all measures than controls; exercise will lead to significant improvements in motor performance and balance,and neurobehavioral and cognitive functioncompared to an equivalent length of time during which they were not participating in training . We further hypothesize that improvements in cortical connectivity and representation will relate directly to functional ones.

Study Population: 80 adults (50 with TBI) will be recruited so that 20 with TBI and 20 healthy volunteers complete the study. Only the TBI group will receive intervention.

Design: Healthy controls with have a single assessment that includes motor, neuropsychological and brain imaging tests. Participants with TBI will have 3 visits with the same motor, neuropsychological and brain imaging tests as the healthy controls. They will perform 2 months of fast elliptical training. . Assessments will occur at 0, 2, and 4 months. The exercise device will be an elliptical trainer that exercises the legs and arms with the emphasis on maintaining a fast speed. Mild resistance will be provided initially and progressively increased once speed is optimized. . The training will be performed in the home 5 days per week for 30 minutes.

Outcome Measures: Performance on complex motor and balance tasks will be assessed with 3D motion capture \& EMG, the Smart Balance Measurement System and the High Level Mobility Assessment Tool (Hi-MAT). Primary outcomes are Hi-MAT score, reaction time during balance testing and the Hamilton Rating Scale for Depression (Ham-D). Secondary outcomes will include measures of motor speed and reaction time, dual task performance, memory, anxiety, sleep quality, and responses to stress. Cortical connectivity will be quantified using resting state functional connectivity magnetic resonance imaging (MRI) and Diffusion Tensor Imaging (DTI), which evaluates white matter tracts. Cortical activation patterns during imagined walking will be quantified with fMRI.
HD-tDCS is delivered on 10 consecutive weekdays, with two sessions per day (in the morning and in the afternoon). For the simulated condition, the investigators maintained the same 30-second acceleration up to a total of 3 mA, followed immediately by a 30-second deceleration. And a maintenance dosage of dexmedetomidine (0.2 - 0.7 mcg/kg per hour).
Vitamin A concentrates are obtained from fish liver oils of relatively low vitamin A content by contacting the oil in countercurrent flow with an organic polar solvent which at low temperatures is not completely miscible with the oil, in a ratio of about 4-20 parts of solvent to one of oil at a temperature below that at which the solvent exhibits complete miscibility with the oil and at which about 20 per cent of the oil is extracted, and evaporating off the solvent to obtain the concentrate containing substantially more vitamin A than the original oil.  In a modified process the oil is contacted with the solvent in two stages, the first stage being conducted at a temperature at which 50 per cent of the oil is extracted, followed by a further extraction at a temperature at which 15 per cent of the oil is extracted into the polar solvent.  Suitable solvents are : hydroxy compounds including alcohols, glycols, hydroxy esters, hydroxy ketones, hydroxy ethers and unsaturated hydroxy compounds; carboxylic acids and their anhydrides; esters, carboxy esters, ether esters, imido esters and unsaturated esters; aldehydes; ketones and diketones; amides and amines; organic carbonates and phosphates; nitro-paraffins; nitriles.  Furfural is particularly suitable.  In a preferred method of performing the extraction the oil, e.g. dog-fish liver oil, is fed into a long vertical column (preferably 50 feet or more) at an intermediate position along its length and the solvent is introduced near the top.  The vitamin impoverished raffinate is drawn off at the top of the column where it is stripped of solvent and may then be stored or passed to another column for further extraction.  The vitamin containing solvent phase is drawn off at the base of the first column and is stripped of solvent to give the vitamin concentrate.  This extract p  may be further concentrated either by returning it to a point near the base of the column, or by extracting the vitamin into water followed by molecular distillation.  Specifications 475,070, 515,468, 2690/43 and 18137/47 (both open to inspection under Sect. 91), are referred to.
OBJECTIVES: This study aimed to assess the knowledge of human papillomavirus (HPV) and attitudes toward HPV vaccination (HPVv) among female patients in Poland, investigating the impact of sociodemographic factors on these aspects. The study also explored awareness of state-funded bivalent vaccination and gauged willingness to vaccinate children, especially in the aspect of the newly introduced nonavalent vaccine.
MATERIAL AND METHODS: An 11-question questionnaire was administered to newly referred patients at a dysplasia consultation center in Kraków University Hospital between February and December 2022. Statistical analysis using IBM SPSS Statistics 25 evaluated sociodemographic characteristics, HPV knowledge, attitudes toward HPVv and correlations among responses.
RESULTS: By December 2022, 187 completed forms were received, primarily from women aged 30-40 years, residing in large cities, and with higher education qualifications. While most were aware of HPV's association with cancer and abnormal cytology, over 40% were unaware of its asymptomatic nature. Higher education is correlated with better HPV awareness. Participants generally showed positive attitudes toward HPVv for themselves and their children, yet only a small fraction had received the vaccine. Education significantly influenced HPV knowledge, with higher education levels linked to better awareness and willingness to vaccinate children. Awareness of HPV is positively correlated with knowledge test performance and vaccination attitudes.
CONCLUSION: The study revealed a lack of awareness regarding government co-financing for the bivalent vaccine. Campaigns endorsing reimbursed vaccination were found to be inadequate, highlighting the need for corrective measures to enhance awareness and improve vaccination rates, particularly for individuals outside the age range between 12 and 13 years relying on self-financing or sporadic government initiatives.
This study combines two programs that have been developed by RAND researchers: Project ALERT (PA) and Getting to Outcomes (GTO). Project ALERT is a widely used drug prevention program for middle school youth. Though it has an evidence-base for effectiveness, the program (like most evidence-based programs in schools) is not run with adequate fidelity representing a large gap between what is developed and tested for effectiveness and what is used in actual practice. Thus, the study will conduct an updated randomized controlled trial of PA and test GTO as a tool to increase adoption and adequate fidelity of the program in schools. GTO's previous evidence suggests it could be effective in public schools, yet this remains an empirical question. A successful demonstration of PA and GTO could fundamentally transform evidence-based prevention's delivery, reach, and thus impact, in the US.
The 24-week Cardiac Rehabilitation intervention will include evaluation, medical and nurse management, aerobic interval training, resistance exercise, psychosocial support, and education. These will initially be delivered in a health center, transitioning to home in 4 stages.
PURPOSE:To obtain a capsule responsive to pH by a method wherein pectin is formed into a film having a specific thickness and the pectin which dissolves in an aq. solution having a pH of at most 3 after immersion in 1% aq. solution of polyvalent metal salt for two hours at 25 deg.C is used as wall membrane and solidified with the polyvalent metal salt. CONSTITUTION:The pectin having a specific dissolving characteristics is formed into a film of 50-150mum thickness and such film is immersed in 1% aq. solution of polyvalent metal salt for two hours at 25 deg.C. A capsule is then produced consisting of the wall membrane contg. the pectin which retains its original film shape in an aq. solution having a pH of at least 7 and its dissolution is unnoticeable but, in an aq. solution having a pH of at most 3, loses its original film shape completely collasping or dissolving. By solidifying this wall membrane with the polyvalent metal salt imparting the aforesaid dissolving characteristics, a microcapsule excellent in pH responsiveness can be obtained which does not dissolve to protect the capsulized substance stably in a neutral solution but, in an acidic solution, dissolves readily to release the capsulized substance. This capsule is useful particularly in drug applications and simple in application technique and efficient and inexpensive to produce.
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with metoprolol tartrate plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Risk of Anaphylactic Reaction. While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
Bifrontal short-pulse ECT was performed once a day for 3 consecutive days. Then,tDCS stimulates the dorsomedial prefrontal cortex. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. 2-mA (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes Twice a day over 10 consecutive sessions.